Short answer
Aurinia Pharmaceuticals Inc. (AUPH) filed an 8-K current report with the SEC on May 11, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets). Aurinia completed Kezar acquisition on May 11, 2026, making Kezar a wholly owned subsidiary.
Aurinia Pharmaceuticals Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Aurinia completed Kezar acquisition on May 11, 2026, making Kezar a wholly owned subsidiary
- Consideration: $6.955 cash per share plus one contingent value right, subject to CVR terms
- 5,927,580 shares tendered, representing approximately 80.24% of outstanding shares
- Minimum tender condition satisfied; merger completed without a stockholder vote under Delaware Section 251(h)
- Out-of-the-money Kezar options cancelled without consideration; in-the-money options received cash spread plus CVRs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aurinia Pharmaceuticals Inc. 8-K filings
Get the next AUPH 8-K as it lands
Follow AUPH for push alerts, or ask the research agent what this filing means.